ResMed (RMD) director Desney Tan gets 1,073 RSUs grant

ResMed Inc. director Desney Tan reported receiving a new equity award from the company.

Accepted by SEC EDGAR 11/24/2025 - 11:20 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

ResMed Inc. director Desney Tan reported receiving a new equity award from the company. On 11/20/2025, he acquired 1,073 shares of ResMed common stock through a grant priced at $0, increasing his directly owned stake to 6,002 shares after the transaction.

The award is in the form of restricted stock units (RSUs), which are shares that Tan will receive once they vest. These RSUs vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date, meaning the shares are subject to a service-based vesting condition tied to time and board tenure.

Insider Trade Summary

Grant/Award: 1,073 shares

Grant/Award 1 txn

Insider Tan Desney

Role Director

Type	Security	Shares	Price	Value
Grant/Award	ResMed Common Stock	1,073	$0.00	$0.00

Holdings After Transaction: ResMed Common Stock — 6,002 shares (Direct)

Footnotes (1)

1. F1. Shares awarded represent Restricted Stock Units. The RSUs vest in full on the earlier of 11/11/2026, or the annual meeting of stockholders in the year following the grant date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ResMed (RMD) report for director Desney Tan?

ResMed (RMD) reported that director Desney Tan acquired 1,073 shares of ResMed common stock on 11/20/2025 through a restricted stock unit award priced at $0.

How many ResMed (RMD) shares does Desney Tan own after this Form 4 transaction?

Following the reported transaction, director Desney Tan beneficially owns 6,002 shares of ResMed Inc. common stock directly.

What type of equity award did ResMed grant to director Desney Tan?

The filing states that the shares awarded to Desney Tan are Restricted Stock Units (RSUs), which convert into ResMed common stock upon vesting.

When do Desney Tan’s ResMed (RMD) RSUs vest?

According to the explanation of responses, the RSUs vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date.

Was any cash paid for the ResMed (RMD) shares acquired by Desney Tan?

No cash was paid for these shares; the Form 4 shows that 1,073 shares of ResMed common stock were acquired at a price of $0 as part of an equity grant.

Is Desney Tan a director or officer of ResMed (RMD)?

The filing identifies Desney Tan as a director of ResMed Inc., with the corresponding box checked under the relationship to issuer section.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tan Desney

(Last) (First) (Middle)

9001 SPECTRUM CENTER BLVD

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock	11/20/2025		A(1)		1,073	A	$0	6,002	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares awarded represent Restricted Stock Units. The RSUs vest in full on the earlier of 11/11/2026, or the annual meeting of stockholders in the year following the grant date.

	Desney Tan, director	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.